165 related articles for article (PubMed ID: 26200610)
1. Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion.
Nakajima R; Abe K; Sakai S
Medicine (Baltimore); 2015 Jul; 94(29):e1010. PubMed ID: 26200610
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
Kim BS; Kim IJ; Kim SJ; Pak K; Kim K
Onkologie; 2011; 34(6):298-303. PubMed ID: 21625182
[TBL] [Abstract][Full Text] [Related]
4. The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.
Sun Y; Yu H; Ma J; Lu P
PLoS One; 2016; 11(8):e0161764. PubMed ID: 27560933
[TBL] [Abstract][Full Text] [Related]
5. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion.
Gupta NC; Rogers JS; Graeber GM; Gregory JL; Waheed U; Mullet D; Atkins M
Chest; 2002 Dec; 122(6):1918-24. PubMed ID: 12475827
[TBL] [Abstract][Full Text] [Related]
6. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
7. [Clinical role of F-18 FDG PET/CT in differentiating malignant and benign pleural effusion in patients with lung cancer].
Liao R; Yang X; Wang S; Zhou Q; Nie Q; Zhong W; Dong S; Wu Y
Zhongguo Fei Ai Za Zhi; 2012 Nov; 15(11):652-5. PubMed ID: 23164351
[TBL] [Abstract][Full Text] [Related]
8. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
9. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
10. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
11. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
12. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography.
Toaff JS; Metser U; Gottfried M; Gur O; Deeb ME; Lievshitz G; Mercer D; Even-Sapir E
Invest Radiol; 2005 Apr; 40(4):204-9. PubMed ID: 15770138
[TBL] [Abstract][Full Text] [Related]
13. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of contrast-enhanced computed tomography and positron emission tomography with 18-FDG in identifying malignant solitary pulmonary nodules.
Dabrowska M; Krenke R; Korczynski P; Maskey-Warzechowska M; Zukowska M; Kunikowska J; Orłowski T; Chazan R
Medicine (Baltimore); 2015 Apr; 94(15):e666. PubMed ID: 25881842
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of the PET-CT score for diagnosis of malignant pleural effusion.
Yang MF; Tong ZH; Wang Z; Zhang YY; Xu LL; Wang XJ; Li W; Wu XZ; Wang W; Zhang YH; Jiang T; Shi HZ
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1457-1467. PubMed ID: 30903197
[TBL] [Abstract][Full Text] [Related]
17. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
18. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis.
Treglia G; Sadeghi R; Annunziata S; Lococo F; Cafarotti S; Bertagna F; Prior JO; Ceriani L; Giovanella L
Acad Radiol; 2014 Jan; 21(1):11-20. PubMed ID: 24331260
[TBL] [Abstract][Full Text] [Related]
20. FDG PET of pleural effusions in patients with non-small cell lung cancer.
Erasmus JJ; McAdams HP; Rossi SE; Goodman PC; Coleman RE; Patz EF
AJR Am J Roentgenol; 2000 Jul; 175(1):245-9. PubMed ID: 10882281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
